Cell adhesion and transcriptional activity - Defining the role of the novel protooncogene LPP

Translational Oncology

Volumn 2, Issue 3, 2009, Pages 107-116

  Grunewald, Thomas Georg Philipp ^a   Pasedag, Saskia M ^b   Butt, Elke ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; LIPOMA PREFERRED PARTNER PROTEIN; UNCLASSIFIED DRUG; ZYXIN;

CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; LEUKEMIA; LUNG CARCINOMA; NONHUMAN; PROTEIN DOMAIN; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; SOFT TISSUE CANCER;

EID: 77349083312     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09112     Document Type: Article

References (115)

1. Petit MM, Meulemans SM, and Van de Ven WJ (2003). The focal adhesion and nuclear targeting capacity of the LIM-containing lipoma-preferred partner (LPP) protein. J Biol Chem 278, 2157-2168.
2. Grunewald TG and Butt E (2008). The LIM and SH3 domain protein family: structural proteins or signal transducers or both? Mol Cancer 7, 31.
3. Benmerah A, Scott M, Poupon V, and Marullo S (2003). Nuclear functions for plasma membrane-associated proteins? Traffic 4, 503-511.
4. Wang Y and Gilmore TD (2003). Zyxin and paxillin proteins: focal adhesion plaque LIM domain proteins go nuclear. Biochim Biophys Acta 1593, 115-120. (Pubitemid 36173479)
5. Petit MM, Mols R, Schoenmakers EF, Mandahl N, and Van de Ven WJ (1996). LPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel member of the LIM protein gene family. Genomics 36, 118-129. (Pubitemid 26277765)
6. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, and Van de Ven WJ (1995). Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet 10, 436-444.
7. Vervenne HB, Crombez KR, Delvaux EL, Janssens V, Van de Ven WJ, and Petit MM (2008). Targeted disruption of the mouse lipoma preferred partner gene. Biochem Biophys Res Commun 379, 368-373.
8. Srichai MB, Konieczkowski M, Padiyar A, Konieczkowski DJ, Mukherjee A, Hayden PS, Kamat S, El-Meanawy MA, Khan S, Mundel P, et al. (2004). A WT1 co-regulator controls podocyte phenotype by shuttling between adhesion structures and nucleus. J Biol Chem 279, 14398-14408. (Pubitemid 38468982)
9. Takafuta T, Saeki M, Fujimoto TT, Fujimura K, and Shapiro SS (2003). A new member of the LIM protein family binds to filamin B and localizes at stress fibers. J Biol Chem 278, 12175-12181. (Pubitemid 36800197)
10. Tu Y, Wu S, Shi X, Chen K, and Wu C (2003). Migfilin and Mig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation. Cell 113, 37-47. (Pubitemid 36411958)
11. Petit MM, Crombez KR, Vervenne HB, Weyns N, and Van de Ven WJ (2005). The tumor suppressor Scrib selectively interacts with specific members of the zyxin family of proteins. FEBS Lett 579, 5061-5068. (Pubitemid 41242853)
12. Kanungo J, Pratt SJ, Marie H, and Longmore GD (2000). Ajuba, a cytosolic LIM protein, shuttles into the nucleus and affects embryonal cell proliferation and fate decisions. Mol Biol Cell 11, 3299-3313. (Pubitemid 30781933)
13. Huggins CJ and Andrulis IL (2008). Cell cycle regulated phosphorylation of LIMD1 in cell lines and expression in human breast cancers. Cancer Lett 267, 55-66.
14. Huggins CJ, Gill M, and Andrulis IL (2007). Identification of rare variants in the hLIMD1 gene in breast cancer. Cancer Genet Cytogenet 178, 36-41. (Pubitemid 47419042)
15. Yi J and Beckerle MC (1998). The human TRIP6 gene encodes a LIM domain protein and maps to chromosome 7q22, a region associated with tumorigenesis. Genomics 49, 314-316. (Pubitemid 28240700)
16. Hirota T, Morisaki T, Nishiyama Y, Marumoto T, Tada K, Hara T, Masuko N, Inagaki M, Hatakeyama K, and Saya H (2000). Zyxin, a regulator of actin filament assembly, targets the mitotic apparatus by interacting with h-warts/LATS1 tumor suppressor. J Cell Biol 149, 1073-1086. (Pubitemid 30354257)
17. Bach I (2000). The LIM domain: regulation by association. Mech Dev 91, 5-17.
18. Dawid IB, Breen JJ, and Toyama R (1998). LIM domains: multiple roles as adapters and functional modifiers in protein interactions. Trends Genet 14, 156-162.
19. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, Orth AP, Vega RG, Sapinoso LM, Moqrich A, et al. (2002). Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci USA 99, 4465-4470. (Pubitemid 34286008)
20. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, et al. (2004). A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 101, 6062-6067. (Pubitemid 38520528)
21. Gorenne I, Nakamoto RK, Phelps CP, Beckerle MC, Somlyo AV, and Somlyo AP (2003). LPP, a LIM protein highly expressed in smooth muscle. Am J Physiol Cell Physiol 285, C674-C685. (Pubitemid 37022066)
22. Petit MM, Fradelizi J, Golsteyn RM, Ayoubi TA, Menichi B, Louvard D, Van de Ven WJ, and Friederich E (2000). LPP, an actin cytoskeleton protein related to zyxin, harbors a nuclear export signal and transcriptional activation capacity. Mol Biol Cell 11, 117-129. (Pubitemid 30075510)
23. Kadrmas JL and Beckerle MC (2004). The LIM domain: from the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol 5, 920-931.
24. Petit MM, Meulemans SM, Alen P, Ayoubi TA, Jansen E, and Van de Ven WJ (2005). The tumor suppressor Scrib interacts with the zyxin-related protein LPP, which shuttles between cell adhesion sites and the nucleus. BMC Cell Biol 6, 1. (Pubitemid 41357608)
25. Crombez KR, Vanoirbeek EM, Van de Ven WJ, and Petit MM (2005). Transactivation functions of the tumor-specific HMGA2/LPP fusion protein are augmented by wild-type HMGA2. Mol Cancer Res 3, 63-70.
26. Li B, Zhuang L, Reinhard M, and Trueb B (2003). The lipoma preferred partner LPP interacts with alpha-actinin. J Cell Sci 116, 1359-1366. (Pubitemid 36410673)
27. Keicher C, Gambaryan S, Schulze E, Marcus K, Meyer HE, and Butt E (2004). Phosphorylation of mouse LASP-1 on threonine 156 by cAMP- and cGMP-dependent protein kinase. Biochem Biophys Res Commun 324, 308-316. (Pubitemid 39311495)
28. Beckerle MC (1998). Spatial control of actin filament assembly: lessons from Listeria. Cell 95, 741-748.
29. Drees B, Friederich E, Fradelizi J, Louvard D, Beckerle MC, and Golsteyn RM (2000). Characterization of the interaction between zyxin and members of the Ena/vasodilator-stimulated phosphoprotein family of proteins. J Biol Chem 275, 22503-22511. (Pubitemid 30621839)
30. Hansen MD and Beckerle MC (2006). Opposing roles of zyxin/LPP ACTA repeats and the LIM domain region in cell-cell adhesion. J Biol Chem 281, 16178-16188.
31. Bear JE, Svitkina TM, Krause M, Schafer DA, Loureiro JJ, Strasser GA, Maly IV, Chaga OY, Cooper JA, Borisy GG, et al. (2002). Antagonism between Ena/VASP proteins and actin filament capping regulates fibroblast motility. Cell 109, 509-521. (Pubitemid 34564477)
32. Hansen MD and Beckerle MC (2008). alpha-Actinin links LPP, but not zyxin, to cadherin-based junctions. Biochem Biophys Res Commun 371, 144-148.
33. Grunewald TG, Kammerer U, Schulze E, Schindler D, Honig A, Zimmer M, and Butt E (2006). Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Exp Cell Res 312, 974-982.
34. Grunewald TG, Kammerer U, Winkler C, Schindler D, Sickmann A, Honig A, and Butt E (2007). Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation. Br J Cancer 96, 296-305. (Pubitemid 46160635)
35. Goicoechea S, Arneman D, Disanza A, Garcia-Mata R, Scita G, and Otey CA (2006). Palladin binds to Eps8 and enhances the formation of dorsal ruffles and podosomes in vascular smooth muscle cells. J Cell Sci 119, 3316-3324. (Pubitemid 44405217)
36. Jin L, Kern MJ, Otey CA, Wamhoff BR, and Somlyo AV (2007). Angiotensin II, focal adhesion kinase, and PRX1 enhance smooth muscle expression of lipoma preferred partner and its newly identified binding partner palladin to promote cell migration. Circ Res 100, 817-825. (Pubitemid 46555686)
37. Gorenne I, Jin L, Yoshida T, Sanders JM, Sarembock IJ, Owens GK, Somlyo AP, and Somlyo AV (2006). LPP expression during in vitro smooth muscle differentiation and stent-induced vascular injury. Circ Res 98, 378-385. (Pubitemid 43755334)
38. Mertins P, Eberl HC, Renkawitz J, Olsen JV, Tremblay ML, Mann M, Ullrich A, and Daub H (2008). Investigation of protein-tyrosine phosphatase 1B function by quantitative proteomics. Mol Cell Proteomics 7, 1763-1777.
39. Dube N, Cheng A, and Tremblay ML (2004). The role of protein tyrosine phosphatase 1B in Ras signaling. Proc Natl Acad Sci USA 101, 1834-1839. (Pubitemid 38228977)
40. Guo B, Sallis RE, Greenall A, Petit MM, Jansen E, Young L, Van de Ven WJ, and Sharrocks AD (2006). The LIM domain protein LPP is a coactivator for the ETS domain transcription factor PEA3. Mol Cell Biol 26, 4529-4538. (Pubitemid 43877573)
41. Higashino F, Yoshida K, Noumi T, Seiki M, and Fujinaga K (1995). Ets-related protein E1A-F can activate three different matrix metalloproteinase gene promoters. Oncogene 10, 1461-1463.
42. Nerlov C, Rorth P, Blasi F, and Johnsen M (1991). Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene 6, 1583-1592. (Pubitemid 21924261)
43. Hua D, Chen B, Bai M, Yu H, Wu X, and Jin W (2009). PEA3 activates VEGF transcription in T47D and SKBR3 breast cancer cells. Acta Biochim Biophys Sin (Shanghai) 41, 63-68.
44. de Launoit Y, Baert JL, Chotteau-Lelievre A, Monte D, Coutte L, Mauen S, Firlej V, Degerny C, and Verreman K (2006). The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochim Biophys Acta 1766, 79-87. (Pubitemid 44202569)
45. de Launoit Y, Chotteau-Lelievre A, Beaudoin C, Coutte L, Netzer S, Brenner C, Huvent I, and Baert JL (2000). The PEA3 group of ETS-related transcription factors. Role in breast cancer metastasis. Adv Exp Med Biol 480, 107-116. (Pubitemid 32176100)
46. Shepherd TG, Kockeritz L, Szrajber MR, Muller WJ, and Hassell JA (2001). The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Curr Biol 11, 1739-1748. (Pubitemid 33092162)
47. Nilsson M, Mertens F, Hoglund M, Mandahl N, and Panagopoulos I (2006). Truncation and fusion of HMGA2 in lipomas with rearrangements of 5q32→q33 and 12q14→q15. Cytogenet Genome Res 112, 60-66. (Pubitemid 41579456)
48. Nilsson M, Panagopoulos I, Mertens F, and Mandahl N (2005). Fusion of the HMGA2 and NFIB genes in lipoma. Virchows Arch 447, 855-858. (Pubitemid 41728875)
49. Majesky MW (2006). Organizing motility: LIM domains, LPP, and smooth muscle migration. Circ Res 98, 306-308.
50. Barrow JR (2006). Wnt/PCP signaling: a veritable polar star in establishing patterns of polarity in embryonic tissues. Semin Cell Dev Biol 17, 185-193.
51. Vervenne HB, Crombez KR, Lambaerts K, Carvalho L, Koppen M, Heisenberg CP, Van de Ven WJ, and Petit MM (2008). Lpp is involved in Wnt/PCP signaling and acts together with Scrib to mediate convergence and extension movements during zebrafish gastrulation. Dev Biol 320, 267-277.
52. Dreesen O and Brivanlou AH (2007). Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 3, 7-17. (Pubitemid 47472808)
53. Carreira-Barbosa F, Kajita M, Morel V, Wada H, Okamoto H, Martinez Arias A, Fujita Y, Wilson SW, and Tada M (2009). Flamingo regulates epiboly and convergence/extension movements through cell cohesive and signalling functions during zebrafish gastrulation. Development 136, 383-392.
54. Tada M and Smith JC (2000). Xwnt11 is a target of Xenopus Brachyury: regulation of gastrulation movements via Dishevelled, but not through the canonical Wnt pathway. Development 127, 2227-2238. (Pubitemid 30386686)
55. Hoffman LM, Nix DA, Benson B, Boot-Hanford R, Gustafsson E, Jamora C, Menzies AS, Goh KL, Jensen CC, Gertler FB, et al. (2003). Targeted disruption of the murine zyxin gene. Mol Cell Biol 23, 70-79. (Pubitemid 36008502)
56. Jin L, Hastings NE, Blackman BR, and Somlyo AV (2009). Mechanical properties of the extracellular matrix alter expression of smooth muscle protein LPP and its partner palladin; relationship to early atherosclerosis and vascular injury. J Muscle Res Cell Motil. DOI 10.007/s10974-009-9173-1.
57. Romanos J, Barisani D, Trynka G, Zhernakova A, Bardella MT, and Wijmenga C (2008). Six new celiac disease loci replicated in an Italian population confirm association to celiac disease. J Med Genet 46, 60-63.
58. Nelander S, Mostad P, and Lindahl P (2003). Prediction of cell type-specific gene modules: identification and initial characterization of a core set of smooth muscle-specific genes. Genome Res 13, 1838-1854. (Pubitemid 36987190)
59. Nix DA, Fradelizi J, Bockholt S, Menichi B, Louvard D, Friederich E, and Beckerle MC (2001). Targeting of zyxin to sites of actin membrane interaction and to the nucleus. J Biol Chem 276, 34759-34767. (Pubitemid 37384475)
60. Wang Y and Gilmore TD (2001). LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains. Biochim Biophys Acta 1538, 260-272. (Pubitemid 32402249)
61. Pipes GC, Creemers EE, and Olson EN (2006). The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev 20, 1545-1556.
62. Petit MM, Lindskog H, Larsson E, Wasteson P, Athley E, Breuer S, Angstenberger M, Hertfelder D, Mattsson E, Nordheim A, et al. (2008). Smooth muscle expression of lipoma preferred partner is mediated by an alternative intronic promoter that is regulated by serum response factor/myocardin. Circ Res 103, 61-69.
63. Cleynen I and Van de Ven WJ (2008). The HMGA proteins: a myriad of functions [Review]. Int J Oncol 32, 289-305. (Pubitemid 351188295)
64. Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, Morton CC, and Chada K (1995). Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 82, 57-65.
65. Reeves R (2001). Molecular biology of HMGA proteins: hubs of nuclear function. Gene 277, 63-81.
66. Sgarra R, Rustighi A, Tessari MA, Di Bernardo J, Altamura S, Fusco A, Manfioletti G, and Giancotti V (2004). Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett 574, 1-8. (Pubitemid 39200885)
67. Fedele M, Berlingieri MT, Scala S, Chiariotti L, Viglietto G, Rippel V, Bullerdiek J, Santoro M, and Fusco A (1998). Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene 17, 413-418. (Pubitemid 28395904)
68. Fedele M, Battista S, Manfioletti G, Croce CM, Giancotti V, and Fusco A (2001). Role of the high mobility group A proteins in human lipomas. Carcinogenesis 22, 1583-1591. (Pubitemid 32952135)
69. Fusco A and Fedele M (2007). Roles of HMGA proteins in cancer. Nat Rev Cancer 7, 899-910.
70. Young AR and Narita M (2007). Oncogenic HMGA2: short or small? Genes Dev 21, 1005-1009.
71. Lemke I, Rogalla P, and Bullerdiek J (2001). Large deletion of part of the HMGIC locus accompanying a t(3;12)(q27 approximately q28;q14 approximately q15) in a lipoma. Cancer Genet Cytogenet 129, 161-164. (Pubitemid 32826310)
72. Lemke I, Rogalla P, and Bullerdiek J (2001). A novel LPP fusion gene indicates the crucial role of truncated LPP proteins in lipomas and pulmonary chondroid hamartomas. Cytogenet Cell Genet 95, 153-156. (Pubitemid 34638951)
73. Petit MM, Swarts S, Bridge JA, and Van de Ven WJ (1998). Expression of reciprocal fusion transcripts of the HMGIC and LPP genes in parosteal lipoma. Cancer Genet Cytogenet 106, 18-23. (Pubitemid 28483427)
74. Ida CM, Wang X, Erickson-Johnson MR, Wenger DE, Blute ML, Nascimento AG, and Oliveira AM (2008). Primary retroperitoneal lipoma: a soft tissue pathology heresy? report of a case with classic histologic, cytogenetics, and molecular genetic features. Am J Surg Pathol 32, 951-954.
75. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, and Moustakas A (2006). Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 174, 175-183. (Pubitemid 44079853)
76. Kubo T, Matsui Y, Goto T, Yukata K, and Yasui N (2006). Overexpression of HMGA2-LPP fusion transcripts promotes expression of the alpha 2 type XI collagen gene. Biochem Biophys Res Commun 340, 476-481. (Pubitemid 43021773)
77. Rogalla P, Kazmierczak B, Meyer-Bolte K, Tran KH, and Bullerdiek J (1998). The t(3;12)(q27;q14-q15) with underlying HMGIC-LPP fusion is not determining an adipocytic phenotype. Genes Chromosomes Cancer 22, 100-104. (Pubitemid 28208801)
78. Lemke I, Rogalla P, Grundmann F, Kunze WP, Haupt R, and Bullerdiek J (2002). Expression of the HMGA2-LPP fusion transcript in only 1 of 61 karyotypically normal pulmonary chondroid hamartomas. Cancer Genet Cytogenet 138, 160-164. (Pubitemid 36020473)
79. Rogalla P, Lemke I, Kazmierczak B, and Bullerdiek J (2000). An identical HMGIC-LPP fusion transcript is consistently expressed in pulmonary chondroid hamartomas with t(3;12)(q27-28;q14-15). Genes Chromosomes Cancer 29, 363-366. (Pubitemid 30824814)
80. von Ahsen I, Rogalla P, and Bullerdiek J (2005). Expression patterns of the LPP-HMGA2 fusion transcript in pulmonary chondroid hamartomas with t(3;12) (q27 approximately 28;q14 approximately 15). Cancer Genet Cytogenet 163, 68-70.
81. Schwindt H, Akasaka T, Zuhlke-Jenisch R, Hans V, Schaller C, Klapper W, Dyer MJ, Siebert R, and Deckert M (2006). Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination. J Neuropathol Exp Neurol 65, 776-782. (Pubitemid 44200318)
82. Jardin F, Gaulard P, Buchonnet G, Contentin N, Lepretre S, Lenain P, Stamatoullas A, Picquenot JM, Duval C, Parmentier F, et al. (2002). Follicular lymphoma without t(14;18) and with BCL-6 rearrangement: a lymphoma subtype with distinct pathological, molecular and clinical characteristics. Leukemia 16, 2309-2317. (Pubitemid 35331848)
83. Jais JP, Haioun C, Molina TJ, Rickman DS, de Reynies A, Berger F, Gisselbrecht C, Briere J, Reyes F, Gaulard P, et al. (2008). The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 22, 1917-1924.
84. Daheron L, Veinstein A, Brizard F, Drabkin H, Lacotte L, Guilhot F, Larsen CJ, Brizard A, and Roche J (2001). Human LPP gene is fused to MLL in a secondary acute leukemia with a t(3;11) (q28;q23). Genes Chromosomes Cancer 31, 382-389. (Pubitemid 32622715)
85. Choi YW, Choi JS, Zheng LT, Lim YJ, Yoon HK, Kim YH, Wang YP, and Lim Y (2007). Comparative genomic hybridization array analysis and real time PCR reveals genomic alterations in squamous cell carcinomas of the lung. Lung Cancer 55, 43-51.
86. Hussenet T, Mallem N, Redon R, Jost B, Aurias A, and du Manoir S (2006). Overlapping 3q28 amplifications in the COMA cell line and undifferentiated primary sarcoma. Cancer Genet Cytogenet 169, 102-113. (Pubitemid 44376419)
87. Sy SM, Lai PB, Pang E, Wong NL, To KF, Johnson PJ, and Wong N (2006). Novel identification of zyxin upregulations in the motile phenotype of hepatocellular carcinoma. Mod Pathol 19, 1108-1116. (Pubitemid 44106726)
88. Amsellem V, Kryszke MH, Hervy M, Subra F, Athman R, Leh H, Brachet-Ducos C, and Auclair C (2005). The actin cytoskeleton-associated protein zyxin acts as a tumor suppressor in Ewing tumor cells. Exp Cell Res 304, 443-456. (Pubitemid 40321122)
89. Grunewald TG, Kammerer U, Kapp M, Eck M, Dietl J, Butt E, and Honig A (2007). Nuclear localization and cytosolic overexpression of LASP-1 correlates with tumor size and nodal-positivity of human breast carcinoma. BMC Cancer 7, 198.
90. Salvi A, Bongarzone I, Micciche F, Arici B, Barlati S, and De Petro G (2009). Proteomic identification of LASP-1 down-regulation after RNAi urokinase silencing in human hepatocellular carcinoma cells. Neoplasia 11, 207-219.
91. Wang B, Feng P, Xiao Z, and Ren EC (2008). LIMand SH3 protein 1 (Lasp1) is a novel p53 transcriptional target involved in hepatocellular carcinoma. J Hepatol 50 (3), 528-537.
92. Tomasetto C, Moog-Lutz C, Regnier CH, Schreiber V, Basset P, and Rio MC (1995). Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains. FEBS Lett 373, 245-249.
93. Tomasetto C, Regnier C, Moog-Lutz C, Mattei MG, Chenard MP, Lidereau R, Basset P, and Rio MC (1995). Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. Genomics 28, 367-376.
94. Grunewald TG, Kammerer U, Kapp M, Eck M, Dietl J, Butt E, and Honig A (2007). Nuclear localization and cytosolic overexpression of LASP-1 correlates with tumor size and nodal-positivity of human breast carcinoma. BMC Cancer 7, 198.
95. Turner DP, Findlay VJ, Kirven AD, Moussa O, and Watson DK (2008). Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression. Mol Biol Cell 19, 3745-3757.
96. Galler AB, Garcia Arguinzonis MI, Baumgartner W, Kuhn M, Smolenski A, Simm A, and Reinhard M (2006). VASP-dependent regulation of actin cytoskeleton rigidity, cell adhesion, and detachment. Histochem Cell Biol 125, 457-474. (Pubitemid 43673510)
97. Krause M, Bear JE, Loureiro JJ, and Gertler FB (2002). The Ena/VASP enigma. J Cell Sci 115, 4721-4726.
98. Dertsiz L, Ozbilim G, Kayisli Y, Gokhan GA, Demircan A, and Kayisli UA (2005). Differential expression of VASP in normal lung tissue and lung adenocarcinomas. Thorax 60, 576-581. (Pubitemid 40966212)
99. Zhang Y, Han G, Fan B, Zhou Y, Zhou X, Wei L, and Zhang J (2009). Green tea (-)-epigallocatechin-3-gallate down-regulates VASP expression and inhibits breast cancer cell migration and invasion by attenuating Rac1 activity. Eur J Pharmacol 606, 172-179.
100. Han G, Fan B, Zhang Y, Zhou X, Wang Y, Dong H, Wei Y, Sun S, Hu M, Zhang J, et al. (2008). Positive regulation of migration and invasion by vasodilator-stimulated phosphoprotein via Rac1 pathway in human breast cancer cells. Oncol Rep 20, 929-939.
101. Parast MM and Otey CA (2000). Characterization of palladin, a novel protein localized to stress fibers and cell adhesions. J Cell Biol 150, 643-656.
102. Goicoechea SM, Bednarski B, Garcia-Mata R, Prentice-Dunn H, Kim HJ, and Otey CA (2009). Palladin contributes to invasive motility in human breast cancer cells. Oncogene 28, 587-598.
103. Pogue-Geile KL, Chen R, Bronner MP, Crnogorac-Jurcevic T, Moyes KW, Dowen S, Otey CA, Crispin DA, George RD, Whitcomb DC, et al. (2006). Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 3, e516. (Pubitemid 46026443)
104. Goicoechea SM, Arneman D, and Otey CA (2008). The role of palladin in actin organization and cell motility. Eur J Cell Biol 87, 517-525.
105. Otey CA, Rachlin A, Moza M, Arneman D, and Carpen O (2005). The palladin/myotilin/myopalladin family of actin-associated scaffolds. Int Rev Cytol 246, 31-58.
106. Nakagawa S and Huibregtse JM (2000). Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol 20, 8244-8253. (Pubitemid 30777740)
107. Nakagawa S, Yano T, Nakagawa K, Takizawa S, Suzuki Y, Yasugi T, Huibregtse JM, and Taketani Y (2004). Analysis of the expression and localisation of a LAP protein, human scribble, in the normal and neoplastic epithelium of uterine cervix. Br J Cancer 90, 194-199. (Pubitemid 38174961)
108. Dow LE, Kauffman JS, Caddy J, Zarbalis K, Peterson AS, Jane SM, Russell SM, and Humbert PO (2007). The tumour-suppressor Scribble dictates cell polarity during directed epithelial migration: regulation of Rho GTPase recruitment to the leading edge. Oncogene 26, 2272-2282. (Pubitemid 46572809)
109. Zhan L, Rosenberg A, Bergami KC, Yu M, Xuan Z, Jaffe AB, Allred C, and Muthuswamy SK (2008). Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell 135, 865-878.
110. Nerlov C, De Cesare D, Pergola F, Caracciolo A, Blasi F, Johnsen M, and Verde P (1992). A regulatory element that mediates co-operation between a PEA3-AP-1 element and an AP-1 site is required for phorbol ester induction of urokinase enhancer activity in HepG2 hepatoma cells. EMBO J 11, 4573-4582.
111. Belot N, Rorive S, Doyen I, Lefranc F, Bruyneel E, Dedecker R, Micik S, Brotchi J, Decaestecker C, Salmon I, et al. (2001). Molecular characterization of cell substratum attachments in human glial tumors relates to prognostic features. Glia 36, 375-390. (Pubitemid 34010065)
112. Sjoblom B, Salmazo A, and Djinovic-Carugo K (2008). alpha-Actinin structure and regulation. Cell Mol Life Sci 65, 2688-2701.
113. Honda K, Yamada T, Hayashida Y, Idogawa M, Sato S, Hasegawa F, Ino Y, Ono M, and Hirohashi S (2005). Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 128, 51-62. (Pubitemid 40039958)
114. Honda K, Yamada T, Endo R, Ino Y, Gotoh M, Tsuda H, Yamada Y, Chiba H, and Hirohashi S (1998). Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol 140, 1383-1393. (Pubitemid 28152987)
115. Fu L, Qin YR, Xie D, Chow HY, Ngai SM, Kwong DL, Li Y, and Guan XY (2007). Identification of alpha-actinin 4 and 67 kDa laminin receptor as stage-specific markers in esophageal cancer via proteomic approaches. Cancer 110, 2672-2681 (Pubitemid 350250336)